About: Bioverativ

An Entity of Type: Subsidiary, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Bioverativ Inc. is an American multinational biotechnology company that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia. Bioverativ competes with Baxalta (acquired by Shire Plc in 2016), Pfizer and Novo Nordisk. The company traded on the NASDAQ exchange under the ticker symbol BIVV until Sanofi completed its acquisition on March 8, 2018.

Property	Value
dbo:abstract	Bioverativ Inc. is an American multinational biotechnology company that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia. Bioverativ competes with Baxalta (acquired by Shire Plc in 2016), Pfizer and Novo Nordisk. The company traded on the NASDAQ exchange under the ticker symbol BIVV until Sanofi completed its acquisition on March 8, 2018. (en)
dbo:foundingYear	2016-01-01 (xsd:gYear)
dbo:industry	dbr:Biotechnology
dbo:keyPerson	dbr:CEO
dbo:numberOfEmployees	400 (xsd:nonNegativeInteger)
dbo:parentCompany	dbr:Sanofi
dbo:product	dbr:Alprolix dbr:Eloctate
dbo:type	dbr:Subsidiary
dbo:wikiPageID	51795199 (xsd:integer)
dbo:wikiPageLength	6916 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1107752903 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Sanofi dbr:Multinational_corporation dbr:Biogen dbr:Pfizer dbc:Biotechnology_companies_of_the_United_States dbr:Corporate_spin-off dbr:Baxalta dbc:2018_mergers_and_acquisitions dbc:American_companies_established_in_2016 dbr:CEO dbc:Pharmaceutical_companies_disestablished_in_2018 dbr:Alprolix dbc:American_subsidiaries_of_foreign_companies dbc:Corporate_spin-offs dbc:Multinational_companies_headquartered_in_the_United_States dbr:Novo_Nordisk dbc:Companies_formerly_listed_on_the_Nasdaq dbr:Haemophilia dbr:Subsidiary dbc:Sanofi dbr:Biotechnology dbc:Biotechnology_companies_established_in_2016 dbr:Cold_agglutinin_disease dbr:Eloctate dbr:Shire_Plc dbr:Securities_and_Exchange_Commission dbr:True_North_Therapeutics
dbp:founded	2016 (xsd:integer) (en)
dbp:industry	dbr:Biotechnology
dbp:keyPeople	(en) John G. Cox (en)
dbp:name	Bioverativ Inc. (en)
dbp:numEmployees	400 (xsd:integer)
dbp:parent	dbr:Sanofi
dbp:products	Alprolix, Eloctate (en)
dbp:type	dbr:Subsidiary
dbp:wikiPageUsesTemplate	dbt:Clade dbt:Infobox_company dbt:Reflist dbt:Short_description dbt:URL
dcterms:subject	dbc:Biotechnology_companies_of_the_United_States dbc:2018_mergers_and_acquisitions dbc:American_companies_established_in_2016 dbc:Pharmaceutical_companies_disestablished_in_2018 dbc:American_subsidiaries_of_foreign_companies dbc:Corporate_spin-offs dbc:Multinational_companies_headquartered_in_the_United_States dbc:Companies_formerly_listed_on_the_Nasdaq dbc:Sanofi dbc:Biotechnology_companies_established_in_2016
rdf:type	owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 dbo:Organisation
rdfs:comment	Bioverativ Inc. is an American multinational biotechnology company that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia. Bioverativ competes with Baxalta (acquired by Shire Plc in 2016), Pfizer and Novo Nordisk. The company traded on the NASDAQ exchange under the ticker symbol BIVV until Sanofi completed its acquisition on March 8, 2018. (en)
rdfs:label	Bioverativ (en)
owl:sameAs	wikidata:Bioverativ https://global.dbpedia.org/id/2cQU2
prov:wasDerivedFrom	wikipedia-en:Bioverativ?oldid=1107752903&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Bioverativ
foaf:name	Bioverativ Inc. (en)
is dbo:subsidiary of	dbr:Sanofi
is dbo:wikiPageRedirects of	dbr:Bioverativ_Inc
is dbo:wikiPageWikiLink of	dbr:Sangamo_Therapeutics dbr:Sanofi dbr:List_of_drugs_granted_breakthrough_therapy_designation dbr:Biogen dbr:List_of_largest_pharmaceutical_mergers_and_acquisitions dbr:List_of_pharmaceutical_companies dbr:Tim_Harris_(biochemist) dbr:List_of_S&P_400_companies dbr:Bioverativ_Inc
is foaf:primaryTopic of	wikipedia-en:Bioverativ